 | Up a level |
Journal Article
Reich, Maria, Spomer, Lina, Klindt, Caroline, Fuchs, Katharina, Stindt, Jan, Deutschmann, Kathleen, Hohne, Johanna, Liaskou, Evaggelia, Hov, Johannes R., Karlsen, Tom H., Beuers, Ulrich, Verheij, Joanne 
ORCID: 0000-0003-1283-630X, Ferreira-Gonzalez, Sofia ORCID: 0000-0001-7776-287X, Hirschfield, Gideon, Forbes, Stuart J., Schramm, Christoph, Esposito, Irene, Nierhoff, Dirk, Fickert, Peter, Fuchs, Claudia Daniela, Trauner, Michael, Garcia-Beccaria, Maria, Gabernet, Gisela ORCID: 0000-0001-7049-9474, Nahnsen, Sven, Mallm, Jan-Philipp, Vogel, Marina, Schoonjans, Kristina, Lautwein, Tobias, Koehrer, Karl, Haeussinger, Dieter, Luedde, Tom, Heikenwalder, Mathias and Keitel, Verena ORCID: 0000-0003-1383-7662
(2021).
Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis.
J. Hepatol., 75 (3).
S. 634 - 648.
AMSTERDAM:
ELSEVIER.
ISSN 1600-0641
Traussnigg, Stefan, Schattenberg, Jorn M. ORCID: 0000-0002-4224-4703, Demir, Muenevver, Wiegand, Johannes, Geier, Andreas, Teuber, Gerlinde, Hofmann, Wolf Peter, Kremer, Andreas E., Spreda, Frank, Kluwe, Johannes, Petersen, Joerg, Boettler, Tobias ORCID: 0000-0002-1195-055X, Halilbasic, Emina, Greinwald, Roland, Proels, Markus, Manns, Michael P., Fickert, Peter and Trauner, Michael H.
(2017).
norUrsodeoxycholic acid (norUDCA) improves non-alcoholic fatty liver disease (NAFLD): Results from a randomized placebo-controlled, double-blind phase IIa study.
Hepatology, 66.
S. 106A - 108.
HOBOKEN:
WILEY.
ISSN 1527-3350
Traussnigg, Stefan, Schattenberg, Jorn M. ORCID: 0000-0002-4224-4703, Demir, Munevver, Wiegand, Johannes, Geier, Andreas, Teuber, Gerfinde, Hofmann, Wolf Peter, Kremer, Andreas E., Spreda, Frank, Kluwe, Johannes, Petersen, Jorg, Boettler, Tobias ORCID: 0000-0002-1195-055X, Rainer, Florian, Halilbasic, Emina, Greinwald, Roland, Prols, Markus, Manns, Michael P., Fickert, Peter and Trauner, Michael ORCID: 0000-0002-1275-6425
(2019).
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial.
Lancet Gastroenterol. Hepatol., 4 (10).
S. 781 - 794.
SAN DIEGO:
ELSEVIER INC.
ISSN 2468-1253